VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF

• US 20100204325A1
• Filed: 02/11/2009
• Published: 08/12/2010
• Est. Priority Date: 02/11/2009
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Hughes, Patrick M., Blanda, Wendy M., Baciu, Peter C.
• Application Number:
  US12/369,705
• Publication Number:
  US 20100204325A1
• Time in Patent Office: Days
• US Class Current: 514/557
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.

Claims

1. An intraocular drug delivery system for treating a retinal condition, comprising:

(a) a bioerodible polymer, and;

(b) a valproic acid associated with the bioerodible polymer.

2. The drug delivery system of claim 1 wherein the polymer comprises from about 10% to about 95% by weight of the drug delivery system.

3. The drug delivery system of claim 1 wherein the valproic acid comprises from about 10% to about 95% by weight of the drug delivery system.

4. The drug delivery system of claim 1 wherein the polymer is a polylactic polyglycolic acid copolymer (PLGA).

5. The drug delivery system of claim 1 wherein the polymer is a polylactic acid polymer (PLA).

6. The drug delivery system of claim 1 wherein the polymer is a high viscosity hyaluronic acid.

7. The drug delivery system of claim 1 wherein the valproic acid is associated with the polymer by being homogenous mixed with the polymer.

8. The drug delivery system of claim 1, wherein the drug delivery system is an implant.

9. The drug delivery system of claim 1, wherein the drug delivery system is a population of microspheres.

10. The drug delivery system of claim 1, wherein the drug delivery system is comprises a solution of the valproic acid in a high viscosity, polymeric hyaluronic acid.

11. An intraocular drug delivery implant for treating a retinal condition comprising 10 to 30 weight percent sodium valproate and 70 to 90 weight PLGA, the implant formed by homogenously mixing the valproate and the PLGA, the mixture then heated to a temperature between about 40 and about 180 C, followed by extrusion of the implant.

13. The method of claim 11, wherein the drug delivery system is administered to the vitreous.

14. The method of claim 11, wherein the drug delivery system is administered to an intrascleral location.

15. The method of claim 14, wherein the drug delivery system is administered to a subtenon location.

12. A method for treating a retinal condition, the method comprising the step of intraocular administration to a patient with a retinal condition of a drug delivery system comprising a bioerodible polymer, and a valproic acid associated with the bioerodible polymer.

16. The method of claim 12, wherein the drug delivery system is a sustained release monolithic implant capable of releasing a therapeutic amount of the valproic acid for between about one week and about one year.

17. A method for treating a macular edema, the method comprising the step of intravitreal administration to a patient with macula edema of a drug delivery system comprising a bioerodible polymer, and a valproic acid associated with the bioerodible polymer.

18. A method for reducing retinal tissue oxidative stress in a human patient, the method comprising the step of intravitreal administration to a human patient with oxidative stress retinal cells of a drug delivery system comprising a bioerodible polymer, and a valproic acid associated with the bioerodible polymer.

19. The method of claim 18, wherein the oxidative stress retinal tissue contains an excess level of a reactive oxygen species selected from the group consisting of peroxinitrate, super oxide, singlet oxygen, hydrogen peroxide, hypochlorite and hydroxy radical.

20. The method of claim 19 wherein the method reduces the excess level of reactive oxygen species to a normal level of reactive oxygen species as determined by a process selected from the group consisting of reactive oxygen sensing dyes, high-performance liquid chromatography (HPLC), immunohistochemistry, Western blotting, enzyme-linked-immunosorbent serologic assay (ELISA), tandem mass spectrometry (MS-MS) and presence or upregulation of oxidative stress response gene/protein or transcription factors.